98%
921
2 minutes
20
Echocardiographic assessment of left ventricular (LV) diastolic function is an integral part of the routine evaluation of patients presenting with symptoms of dyspnea or clinical concerns for heart failure. Given the presence of diastolic dysfunction in many cardiovascular diseases, clinical reports should include comments on diastolic function and/or left atrial (LA) pressure whenever possible. Since the publication of the 2016 ASE/EACVI guidelines for assessment of LV diastolic function, new data on additional echocardiographic variables as left atrial strain and their association with LV filling pressures have emerged. Moreover, prognostic data from epidemiologic studies have demonstrated the association of echocardiographic measures with the subsequent development of heart failure. This update provides a contemporary approach for the assessment of LV diastolic function and the estimation of LA pressure in the general population of patients in sinus rhythm referred for echocardiographic evaluation, and in special populations that require deviation from the general approach. The update also discusses the application of echocardiography in the diagnosis of patients with heart failure with preserved LV ejection fraction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.echo.2025.03.011 | DOI Listing |
Cardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Objectives: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) risk, yet the mechanisms remain unclear. This study aimed to evaluate myocardial structure, function, and tissue characterization using cardiovascular magnetic resonance (CMR) in RA patients and explore associations with RA disease severity.
Methods: This mixed case-control study included 48 RA patients and 34 age- and sex-matched controls.
Front Cardiovasc Med
August 2025
Department of Cardiovascular Medicine, Fengxian Central Hospital, Shanghai, China.
Background: Arterial compliance is an independent predictor of diastolic dysfunction. Invasive catheterization can accurately reflect diastolic function. However, studies on the invasive assessment of diastolic function are currently limited.
View Article and Find Full Text PDFCardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Front Endocrinol (Lausanne)
September 2025
Department of Medical Sciences, University of Turin, Turin, Italy.
Context: Cardiometabolic complications are increasingly recognized in congenital adrenal hyperplasia (CAH) due to 21β-hydroxylase deficiency, but adult data remain limited.
Objective: To evaluate cardiovascular and metabolic alterations in adult patients with classic CAH under glucocorticoid treatment, compared to matched controls.
Methods: A cross-sectional study was conducted on adults with classic CAH and sex- and BMI-matched controls.